Table 2.
Characteristics of eligible studies referring to the association between PlA1/A2 gene polymorphism and adverse cardiovascular events.
| Source | Number of patients (PlA1/PlA2) | Study design | Aspirin dosage (mg) | Mean follow-up | Outcomes (PlA1/PlA2) | |
|---|---|---|---|---|---|---|
| Addad F et al., 2010 | 188(104/84) | Cohort study | 250 | 1 year | Death | (10/1) |
| Kastrati A et al., 2000 | 1759(1234/525) | Cohort study | 200 | 1 month | Death | (4/3) |
| MI | (51/24) | |||||
| TVR | (28/12) | |||||
| Laule M et al., 1999 | 653(470/183) | Case-control study | 100 | 1 month | MI | (8/4) |
| Death | (1/0) | |||||
| TVR | (18/10) | |||||
| Lopes NH et al., 2004 | 562(450/112) | Cohort study | UK | 3 years | Death | (41/2) |
| MI | (37/9) | |||||
| TVR | (44/2) | |||||
| Syros G et al., 2009 | 200(144/56) | Cohort study | UK | 1 year | Death | (2/2) |
| MI | (1/0) | |||||
| TVR | (8/1) | |||||
| Walter DH et al., 1997 | 318(255/63) | Cohort study | 100–500 | 1 month | Death | (0/0) |
| MI | (3/4) | |||||
| Walter DH et al., 2001 | 324(253/71) | Cohort study | 100 | 6 months | Death | (9/0) |
| MI | (9/2) | |||||
| TVR | (83/30) | |||||
| Wheeler GL et al., 2002 | 87(66/21) | Cohort study | UK | 24 h | Death | (0/0) |
| MI | (4/0) | |||||
MI, myocardial infarction; TVR, target vessel revascularization; UK, unknown.